Alza Corp. will acquire Menlo, CA-based Sequus in a transaction valued at approximately $580 million, the companies announced.
PALO ALTO, CALIFORNIA - Alza Corp. will acquire Menlo, CA-based Sequus in a transaction valued at approximately $580 million, the companies announced.
"The acquisition of Sequus and its product, Doxil,® is a logical extension of our strategy and adds a proven oncology therapeutic product to our portfolio along with a core technology platform for additional oncology products," said Ernest Mario, M.D., ALZA's chairman and CEO.
Sequus' major product is Doxil, ® an anticancer drug. ALZA's main products include Procardia XL® for the treatment of hypertension and Ethyol® for the reduction of cumulative kidney toxicity associated with repeated doses of the chemotherapy drug cisplatin in advanced ovarian cancer or non-small-cell lung cancer. ALZA also developed the transdermal patch in Nicoderm CQ for the treatment of smoking.
ALZA currently employs approximately 80 oncology sales reps and 280 urology and primary care sales reps. Sequus's oncology sales force is substantially smaller than ALZA's, but will extend ALZA's influence in the oncology community.
"This is an outstanding opportunity for Sequus and our shareholders," said Dr. I. Craig Henderson, Sequus' chairman and CEO. "With this merger, Sequus shareholders will be able to benefit in the growth of Doxil through an integrated sales force almost three times our current size."
Under the terms of the agreement, ALZA will acquire all of Sequus's outstanding stock in a tax-free, stock-for-stock transaction. Sequus shareholders will receive 0.4 shares of ALZA common stock for each share of Sequus common stock.
The transaction, subject to regulatory and Sequus shareholder approval, is expected to close in late 1998 or early 1999. PR
GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease
May 14th 2025Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.